APLT

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).

Wall Street analysts forecast APLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLT is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Applied Therapeutics Inc revenue for the last quarter amounts to 1,000K USD, increased 719.67 % YoY.

Applied Therapeutics Inc. EPS for the last quarter amounts to -0.13 USD, decreased -72.92 % YoY.

Applied Therapeutics Inc (APLT) has 35 emplpoyees as of January 09 2026.

Today APLT has the market capitalization of 14.46M USD.